Shay Capital’s Enzo Biochem, Inc. ENZ Stock Holding History

Shay Capital’s Portfolio ENZ Stock Details ENZ Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q4	–	Sell	-62,500	Closed	-$87.5K	–	438
2023 Q3	$87.5K	Buy	+62,500	New	+$94.2K	0.01%	301

Other funds holding ENZ

HFA

Harbert Fund Advisors Birmingham, Alabama $3.03M AUM 40.55% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

TCM

Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return

PCM

Potomac Capital Management New York $115M AUM

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

RBF Capital San Francisco, California $2.05B AUM 29.64% 1-Year Est. Return

AFM

Anson Funds Management Dallas, Texas $2.29B AUM 370.24% 1-Year Est. Return

Shay Capital's ENZ Position: Q4 2023 in Review

Shay Capital sold out of Enzo Biochem, Inc. (ENZ) in Q4 2023, closing a stake of 62,500 shares — an estimated $87.5K sold.

Shay Capital first reported a position in ENZ in Q3 2023 and held it in 1 quarter. The position peaked at $87.5K in Q3 2023. 46 funds tracked by Wall St. Rank hold ENZ as of Q4 2023.

Shay Capital reported no remaining Enzo Biochem, Inc. position as of Q4 2023 after selling out during the quarter.
Shay Capital sold 62,500 Enzo Biochem, Inc. shares in Q4 2023, an estimated $87.5K.
Shay Capital first reported a position in Enzo Biochem, Inc. in Q3 2023 and held it in 1 quarter.
Shay Capital's Enzo Biochem, Inc. position peaked at $87.5K in Q3 2023.
46 funds tracked by Wall St. Rank held Enzo Biochem, Inc. as of Q4 2023.

Based on Shay Capital's 13F filing for Q4 2023, filed 14 Feb 2024.